Savara (NASDAQ:SVRA) Trading 4.1% Higher – Still a Buy?

Savara Inc (NASDAQ:SVRA) shot up 4.1% on Tuesday . The company traded as high as $3.05 and last traded at $3.02. 101,330 shares changed hands during trading, a decline of 92% from the average session volume of 1,328,423 shares. The stock had previously closed at $2.90.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the company. HC Wainwright restated a “buy” rating and set a $6.00 price objective on shares of Savara in a report on Friday, March 28th. Wells Fargo & Company initiated coverage on shares of Savara in a report on Friday, December 20th. They issued an “overweight” rating and a $8.00 price target on the stock. Finally, JMP Securities reissued a “market outperform” rating and set a $9.00 price objective on shares of Savara in a report on Thursday, December 19th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $8.83.

Savara Stock Performance

The firm’s 50 day simple moving average is $2.73 and its two-hundred day simple moving average is $3.11. The company has a quick ratio of 17.70, a current ratio of 17.70 and a debt-to-equity ratio of 0.13. The stock has a market cap of $505.81 million, a P/E ratio of -6.81 and a beta of 0.52.

Savara (NASDAQ:SVRA) last released its quarterly earnings data on Thursday, March 27th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.02). The company had revenue of $0.27 million for the quarter. As a group, equities research analysts predict that Savara Inc will post -0.45 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Savara

Several hedge funds and other institutional investors have recently modified their holdings of the company. Cibc World Markets Corp acquired a new position in Savara during the 4th quarter valued at about $33,000. XTX Topco Ltd acquired a new stake in Savara in the 4th quarter valued at approximately $34,000. Ameriprise Financial Inc. acquired a new position in Savara during the 4th quarter worth $37,000. KLP Kapitalforvaltning AS bought a new position in shares of Savara in the fourth quarter worth $41,000. Finally, Hsbc Holdings PLC acquired a new position in shares of Savara during the fourth quarter valued at $48,000. Institutional investors and hedge funds own 87.93% of the company’s stock.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.